What is Domperidone (Motility agent)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Domperidone is a dopamine D2-receptor antagonist that is used to treat nausea, vomiting, and certain gastrointestinal disorders, with a recommended starting dose of 10 mg 3 times a day, although its use is limited by cardiovascular safety considerations, particularly QT prolongation and ventricular tachycardia, as reported in a study published in Clinical Gastroenterology and Hepatology 1.

Key Points

  • Domperidone does not readily cross the blood-brain barrier, resulting in fewer central side effects compared to metoclopramide, as noted in the study 1.
  • The medication has modest efficacy in improving symptom scores in patients with gastroparesis, with 68% of patients showing improvement in a single-center cohort study, although 7% experienced cardiac side effects requiring drug cessation 1.
  • Due to cardiovascular safety concerns, the dose should probably not be escalated to 20 mg 4 times a day, and patients with existing heart conditions or those taking other medications that affect heart rhythm should use domperidone with caution under medical supervision.

Important Considerations

  • Domperidone is not FDA-approved in the United States and is only available through an FDA investigational drug application, as mentioned in the study 1.
  • Patients should be monitored for cardiac side effects, and the medication should be used with caution in patients with a history of heart conditions or those taking other medications that may affect heart rhythm.
  • The use of domperidone should be weighed against the potential benefits and risks, particularly in patients with refractory gastroparesis, and alternative treatment options should be considered, such as 5-HT3 receptor antagonists or neurokinin receptor antagonists, as discussed in the study 1.

From the FDA Drug Label

Domperidone is a D2 dopamine receptor antagonist that blocks the agonistic action of fescue alkaloids at the cellular level. Domperidone is a D2 dopamine receptor antagonist. Domperidone is a motility agent that acts as a D2 dopamine receptor antagonist 2 2.

  • It works by blocking the action of dopamine in the gastrointestinal tract, which helps to enhance motility.
  • The exact mechanism of action is not fully described in the provided drug labels, but it is known to have effects on the gastrointestinal system.

From the Research

Definition and Mechanism of Action

  • Domperidone is a dopamine receptor antagonist with peripheral prokinetic and central antiemetic properties 3, 4, 5.
  • It acts as an antiemetic and a prokinetic agent through its effects on the chemoreceptor trigger zone and motor function of the stomach and small intestine 5.

Clinical Applications

  • Domperidone is used to treat nausea and vomiting, gastroparesis, and as a galactogogue (to promote lactation) 3, 4, 5.
  • It is also used to treat other conditions such as dumping syndrome, cyclic vomiting, and conditioned vomiting 3.

Safety Profile

  • Domperidone has been associated with prolongation of the QTc interval, which can increase the risk of cardiac arrhythmias 3, 4, 6.
  • The risk of cardiac toxicity is higher when domperidone is co-administered with QT-interacting medications 6.
  • Domperidone should not be administered to subjects with pre-existing QT prolongation/LQTS, subjects receiving drugs that inhibit CYP3A4, subjects with electrolyte abnormalities or with other risk factors for QT-prolongation 4.

Efficacy

  • Domperidone has been shown to be effective in reducing nausea and vomiting in patients with gastroparesis and other conditions 3, 5, 7.
  • It has a low risk of adverse cardiovascular events while exhibiting good clinical efficacy at high doses 3.

Related Questions

What are the differences between alisapride and domperidone (motility agents) in clinical practice?
What are the potential interactions between domperidone and levosulpiride?
Can domperidone be given with Augmentin (amoxicillin/clavulanate) and levocetirizine?
Can naproxen and domperidone be given to a 13-year-old?
What is the recommended dose of domperidone (antiemetic medication) for a 5-year-old child weighing 14.9kg?
What is the significance of elevated Thyroid-Stimulating Hormone (TSH) and Thyroxine (T4) levels in a patient 4 months post-thyroidectomy and 1 month post-Radioactive Iodine (RAI) therapy, currently on 175 micrograms of Levothyroxine (T4 replacement therapy)?
What is the management approach for a patient 4 months post-thyroidectomy and 1 month post-radioactive iodine (RAI) therapy, currently on 175 micrograms of Levothyroxine (thyroxine), presenting with elevated Thyroid-Stimulating Hormone (TSH) and thyroxine (T4) levels, with a target TSH of less than 0.1?
What is the management approach for a patient with a mechanical (metallic) heart valve presenting with gastrointestinal (GI) hemorrhage?
What is the treatment for a 56-year-old man with Small Cell Lung Cancer (SCLC) under pembrolizumab (pembrolizumab) who develops diarrhea (4-5 stools per day) despite loperamide, with options including prednisone, infliximab, or cyclophosphamide?
What is the dose of dutasteride (Dutasteride) in the treatment of frontal fibrosing alopecia?
Is an alpha agonist like guanfacine a reasonable option for a patient with Attention Deficit Hyperactivity Disorder (ADHD) and Post-Traumatic Stress Disorder (PTSD) who failed a trial of Strattera (atomoxetine) and cannot take stimulants due to a history of seizures, while already on 5mg of Prazosin (prazosin) for PTSD?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.